Viatris
VTRS
$16.88
-0.35%
Viatris Inc. is a global healthcare company formed in November 2020 through the combination of Pfizer's Upjohn unit and Mylan, specializing in generic and specialty pharmaceuticals, with a portfolio that includes legacy brands like Lipitor, Norvasc, Lyrica, and Viagra, alongside generics and biosimilars. As one of the largest generic drug manufacturers worldwide, Viatris serves over 165 countries, with generics and biosimilars contributing roughly 40% of sales and the remaining 60% from its established brand portfolio. The current investor narrative centers on the company's strategic transformation, including a focus on high-growth therapeutic areas like dermatology, ophthalmology, and gastroenterology, while managing debt reduction and navigating the challenges of patent expirations and pricing pressures in the generic drug industry. Recent attention has been driven by a strong 1-year stock performance (+63.4%) and a return to profitability in Q1 2026, signaling a potential turnaround story.…
VTRS
Viatris
$16.88
Investment Opinion: Should I buy VTRS Today?
Based on the analysis, Viatris is rated as a Buy, with the thesis that the company is successfully executing a turnaround, as evidenced by returning revenue growth and strong free cash flow, while trading at a significant discount to its peers. The average analyst target price of $18.50 implies a 9.6% upside, and the high target of $23.00 suggests even greater potential if the company exceeds expectations. The stock's forward PE of 6.33x is attractive relative to the sector, and the PS ratio of 1.02x is well below the industry average of 3-4x, indicating undervaluation.
Sign up to view all
VTRS 12-Month Price Forecast
The AI assessment is bullish on Viatris, with medium confidence, based on the company's improving fundamentals and attractive valuation. The return to revenue growth, strong free cash flow, and low forward PE suggest that the market is not fully pricing in the earnings recovery. However, the high debt load and margin compression introduce uncertainty, warranting a medium confidence level. The stance would be upgraded to high confidence if the company delivers consistent earnings growth and demonstrates margin stabilization, while a downgrade to neutral would occur if revenue growth decelerates or if the stock reaches the analyst average target without further catalysts.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Viatris's 12-month outlook, with a consensus price target around $18.50 and implied upside of +9.6% versus the current price.
Average Target
$18.50
0 analysts
Implied Upside
+9.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$12 - $23
Analyst target range
With 8 analysts covering Viatris, the consensus recommendation is 'none' (mixed), but the average target price of $18.50 implies an upside of 9.6% from the current price of $16.88. The distribution of ratings includes Overweight (Barclays), Buy (Truist, Argus, Jefferies), and Neutral (JP Morgan, Piper Sandler), indicating a moderately bullish sentiment, though the lack of a clear consensus suggests uncertainty about the company's growth trajectory. The target price range spans from $12.00 (low) to $23.00 (high), with the high target assuming successful execution of the strategic plan and margin expansion, while the low target reflects risks from generic competition and potential regulatory issues. Recent ratings actions have been mostly positive, with Argus upgrading from Hold to Buy in January 2026, but Barclays previously downgraded to Underweight in February 2025, showing a divergence in analyst views.
Bulls vs Bears: VTRS Investment Factors
Viatris presents a compelling turnaround story, with strong evidence of improving fundamentals: revenue growth has resumed, free cash flow is robust, and the stock is undervalued on forward earnings. However, the company faces significant challenges, including high debt, margin compression, and a mixed analyst outlook. The bull case currently has stronger evidence, driven by the tangible operational improvements and attractive valuation, but the bear case highlights the risks of leverage and competitive pressures. The most important tension is whether the company can sustain its recent revenue growth and margin expansion while deleveraging, as this will determine if the stock re-rates higher or remains range-bound.
Bullish
- Return to Revenue Growth: Q1 2026 revenue grew 8.1% YoY to $3.517B, reversing a multi-year decline trend. This marks a pivotal inflection point, signaling that the portfolio transformation and focus on growth areas are starting to pay off.
- Strong Free Cash Flow Generation: TTM free cash flow stands at $1.71B, providing ample capacity for debt reduction, dividends, and strategic investments. This cash generation supports the company's deleveraging efforts and financial flexibility.
- Undervalued on Forward Earnings: With a forward PE of 6.33x, the market is pricing in a strong earnings recovery. This is a significant discount to the broader pharmaceutical sector, suggesting potential upside if the company delivers on its profitability targets.
- Positive Analyst Sentiment: The average analyst target price of $18.50 implies a 9.6% upside from the current price of $16.88. Recent upgrades from Argus (Hold to Buy) and a high target of $23.00 indicate growing confidence in the turnaround.
Bearish
- High Debt Burden: Debt-to-equity ratio stands at 0.999, indicating a highly leveraged balance sheet. This limits financial flexibility and increases vulnerability to interest rate hikes or earnings shortfalls, as interest expenses remain elevated.
- Gross Margin Compression: Gross margin declined to 32.9% in Q1 2026 from 35.7% in the prior year quarter, reflecting ongoing pricing pressures in the generic business. This trend could persist, eroding profitability if not offset by cost cuts.
- Negative Trailing EPS: Trailing twelve-month EPS is -$0.24, and the trailing PE is -4.15x, indicating the company has not yet consistently returned to profitability. The Q1 2026 net income of $176.4M is a positive sign, but sustainability remains unproven.
- Mixed Analyst Ratings: The consensus recommendation is 'none' (mixed), with ratings ranging from Overweight to Neutral. This lack of clear consensus suggests uncertainty about the company's growth trajectory and execution risks.
VTRS Technical Analysis
Viatris is in a clear uptrend over the past year, with the stock price rising 63.4% from a 52-week low of $9.43 to a current price of $16.88, which is near the upper end of its 52-week range (currently at 91.8% of the range, calculated as (16.88-9.43)/(18.39-9.43)). This positioning near the 52-week high of $18.39 suggests strong momentum, though it also raises the risk of overextension, especially after a recent pullback from the high. The stock has outperformed the S&P 500 significantly, with a relative strength of 44.8% over the past year, indicating robust investor interest in the healthcare sector.
Beta
0.88
0.88x market volatility
Max Drawdown
-19.6%
Largest decline past year
52-Week Range
$9-$18
Price range past year
Annual Return
+63.4%
Cumulative gain past year
| Period | VTRS Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | -0.4% |
| 3m | +6.3% | +4.5% |
| 6m | +19.2% | +13.9% |
| 1y | +63.4% | +19.0% |
| ytd | +35.5% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VTRS Fundamental Analysis
Viatris reported Q1 2026 revenue of $3.517 billion, up 8.1% year-over-year, marking a return to growth after a period of declining sales, with the Brands segment contributing $2.3325 billion and Generics $1.1772 billion. The company achieved a net income of $176.4 million in Q1 2026, a significant improvement from the net loss of $3.042 billion in Q1 2025, which was impacted by a one-time impairment charge. Gross margin stood at 32.9% in Q1 2026, down from 35.7% in the prior year quarter, reflecting ongoing pricing pressures in the generic business, but the EBITDA margin improved to 18.3% from a negative figure a year ago, indicating operational efficiency gains.
Quarterly Revenue
$3.5B
2026-03
Revenue YoY Growth
+8.1%
YoY Comparison
Gross Margin
32.9%
Latest Quarter
Free Cash Flow
$1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VTRS Overvalued?
Given that Viatris has negative trailing twelve-month net income (EPS of -$0.24), the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 1.02x, which is below the industry average for pharmaceutical companies, suggesting a potential undervaluation. The forward PE ratio of 6.33x implies the market expects earnings to recover strongly, as the company returns to profitability, and the gap between the negative trailing PE and positive forward PE highlights this anticipated turnaround. Compared to the sector, Viatris trades at a significant discount, with a PS ratio of 1.02x versus the industry average of around 3-4x, reflecting its lower growth prospects and higher debt load, but this discount may be unwarranted given its improving fundamentals and strong free cash flow generation.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-70.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Viatris carries a substantial debt load, with a debt-to-equity ratio of 0.999, which amplifies financial risk, especially if interest rates remain elevated. The company's gross margin has compressed to 32.9% in Q1 2026 from 35.7% a year earlier, reflecting pricing pressures in generics that could persist. While free cash flow is strong at $1.71B TTM, the company's net income has been volatile, swinging from a massive loss in Q1 2025 to a modest profit in Q1 2026, indicating that earnings visibility is low. The negative trailing EPS of -$0.24 underscores that the company has not yet consistently returned to profitability, and any operational misstep could delay the anticipated earnings recovery.
FAQ
The key risks of holding VTRS include: 1) Financial risk from high leverage, with a debt-to-equity ratio of 0.999, which could strain cash flows if interest rates rise or earnings disappoint. 2) Competitive risk in the generic drug market, which has led to gross margin compression from 35.7% to 32.9% in Q1 2026. 3) Regulatory risk, as changes in drug pricing policies could impact the legacy brand portfolio. 4) Execution risk, as the company's turnaround depends on successful debt reduction and growth in key therapeutic areas. The most severe risk is a failure to sustain revenue growth, which could lead to a decline toward the 52-week low of $9.43, representing a potential loss of 44% from the current price.
The 12-month forecast for VTRS is moderately bullish, with a base case probability of 50% and a target range of $17.00-$19.00, aligning with the analyst average target of $18.50. The bull case, with a 30% probability, targets $20.00-$23.00, driven by successful execution of the strategic plan and margin expansion. The bear case, with a 20% probability, targets $12.00-$14.00, reflecting risks from competitive pressures and regulatory actions. The most likely scenario is the base case, which assumes continued gradual improvement in revenue and margins, leading to modest upside. Investors should monitor quarterly earnings to gauge whether the company is on track to meet these expectations.
VTRS appears undervalued based on several metrics. The PS ratio of 1.02x is well below the industry average of 3-4x, and the forward PE of 6.33x is significantly lower than the broader pharmaceutical sector. The stock also trades at a price-to-cash flow ratio of 6.29x, indicating that the market is not fully valuing its cash generation. The negative trailing PE reflects past losses, but the forward PE suggests the market expects a strong earnings recovery. This undervaluation implies that the market is skeptical about the sustainability of the turnaround, but if the company delivers on its earnings targets, the stock could re-rate higher. Overall, VTRS is undervalued relative to its history and peers, offering potential upside for patient investors.
VTRS appears to be a good buy for investors with a medium-to-long-term horizon, given its attractive valuation and improving fundamentals. The stock trades at a forward PE of 6.33x, which is a significant discount to the sector, and the average analyst target of $18.50 implies a 9.6% upside. The company has returned to revenue growth (8.1% YoY in Q1 2026) and generates strong free cash flow of $1.71B TTM, providing a margin of safety. However, the high debt-to-equity ratio of 0.999 and gross margin compression are key risks. For investors comfortable with these risks, VTRS offers a compelling risk/reward profile, but it may not be suitable for those seeking low-volatility or income-focused investments.
VTRS is better suited for long-term investment, given its turnaround nature and the time required for debt reduction and earnings recovery to play out. The stock's beta of 0.893 indicates lower volatility than the market, but it has experienced significant price swings, as seen in its 63.4% rally over the past year. The company's dividend yield of 3.85% provides some income, but the payout ratio is negative due to losses, so dividend sustainability is a concern. For short-term traders, the stock's momentum and relative strength could offer opportunities, but the risk of a pullback after a strong rally is elevated. A minimum holding period of 12-18 months is recommended to allow the turnaround to materialize and for the stock to reach its intrinsic value.